Atypical antipsychotics for schizophrenia : combination therapy and high doses / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

CADTH optimal use report.

CADTH optimal use report

Language:

English

Subjects (All):

Schizophrenia--Treatment.

Schizophrenia.

Physical Description:

1 online resource (vi, 46 pages).

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Healt, 2011.

Summary:

The objectives of this project are to: 1. Identify and appraise the clinical and cost-effectiveness evidence pertaining to use of atypical antipsychotic (AAP) combination and high-dose treatment strategies in the defined population and to develop evidence-based optimal use recommendations for these strategies. 2. Identify current utilization of AAP combination and high-dose treatment strategies in Canada. 3. Identify current practices of physicians and patients regarding the use of AAP combination and high-dose treatment strategies in Canada. 4. Identify differences (i.e., the gaps) between optimal prescribing and use of AAP combination and high-dose treatment strategies, as well as actual current utilization and practice. 5. Identify potential barriers to optimal use of AAP combination and high-dose treatment strategies. 6. Identify key messages to encourage optimal prescribing and use of AAP combination and high-dose treatment strategies. 7. Identify effective activities and strategies (interventions), which could be directed toward a variety of audiences such as health and allied health professionals, patients, or government decision-makers, to encourage optimal prescribing and use of AAP combination therapy and high-dose treatment strategies. 8. Develop intervention tools to support optimal prescribing and use of AAP combination therapy and high-dose treatment strategies. 9. Support implementation of tools and evaluation. 10. Develop evaluation mechanisms to measure the impact of intervention tools.

Contents:

Contributors from CADTH

COMPUS Expert Review Committee

Members

Specialist Expert Members

Conflicts of Interest

ABBREVIATIONS

1. INTRODUCTION

1.1 The COMPUS Expert Review Committee

2. ISSUE

2.1 Schizophrenia

3. OBJECTIVE

4. PROJECT OVERVIEW

5. RESEARCH QUESTIONS

5.1 Clinical

5.2 Economic Evaluation and Current Utilization

5.3 Current Practice

6. METHODS

6.1 Clinical

6.2 Economic

6.3 Current Practice

6.4 Development of Optimal Use Recommendations

6.5 Identification of Gaps and Key Messages

7. EXECUTION OF THE PROJECT

8. DELIVERABLES

REFERENCES

APPENDIX 1 Literature Search Strategy

APPENDIX 2 Overview of Process for Assessing the Applicability of Existing Systematic Reviews and Meta-analyses

APPENDIX 3 SIGN 50* - Randomized Controlled Trial Quality Assessment Tool.

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.